Press release
Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH
Webinar scheduled for Thursday, November 17, 2022, at 11:00 a.m. ESTFeaturing key opinion leader discussion on current treatment landscapeNEW YORK, Nov. 9,
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"Webinar scheduled for Thursday, November 17, 2022, at 11:00 a.m. ESTFeaturing key opinion leader discussion on current treatment landscapeNEW YORK, Nov. 9, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that it will host a data presentation on newly released safety and efficacy data from the Phase 2 trial of its oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes (\"T2D\") patients with non-alcoholic steatohepatitis (\"NASH\") on Thursday, November 17, 2022, at 11:00 a.m. Eastern Standard Time.\nProfessor Yaron Ilan, M.D., Director of the Department of Medicine at the Hebrew University-Hadassah Medical Center, and Joel Neutel, M.D., Director of Research, at the Orange County Research Center and Memorial Research Medical Clinic, will provide commentary on this data and the need for a NASH treatment that is safe and well-tolerated.\nThe formal presentation will be followed by a live question and answer session with Dr. Ilan and Dr. Neutel, who served as primary investigators of this study.\nTo register for the event, please click the following link: https://touchconference.zoom.us/webinar/register/WN_dy3jzksKQA6kBKZdT5a0_g\nThe live and archived webinar of this event may be accessed on Oramed's website under Events and Presentations.\nProfessor Yaron Ilan, M.D.Dr. Yaron Ilan is the Director of the Department of Medicine at the Hebrew University-Hadassah Medical Center. Dr. Ilan served as the Vice Dean of the Hebrew University-Hadassah Medical School. Dr. Ilan was a Visiting Professor at Harvard University, working on novel immunotherapies. His main area of research is development of immunomodulatory drugs for fatty liver disease, diabetes, inflammatory bowel disease and liver cancer. Dr. Ilan holds over 50 patents for discoveries based on his innovative research and has authored more than 300 articles. He is the inventor of several drugs and medical devices developed by pharmaceutical companies, several that have reached the clinical market. Dr. Ilan is the founder of several companies and is a medical director and advisor for biotech companies.\nJoel Neutel, M.D.Dr. Neutel serves as Director of Research at the Orange County Research Center...